These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9440093)

  • 21. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin.
    Steffen HM; Brunner R; Müller R; Degenhardt S; Pollok M; Lang R; Baldamus CA
    Contrib Nephrol; 1989; 76():292-8. PubMed ID: 2582783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant erythropoietin acutely decreases renal perfusion and decouples the renin-angiotensin-aldosterone system.
    Aachmann-Andersen NJ; Christensen SJ; Lisbjerg K; Oturai P; Johansson PI; Holstein-Rathlou NH; Olsen NV
    Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29504258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of renal anemia with recombinant human erythropoietin].
    Burghard R; Gordjani N; Leititis JU
    Monatsschr Kinderheilkd; 1989 Mar; 137(3):174-7. PubMed ID: 2716749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in blood and plasma volume during treatment with recombinant human erythropoietin.
    Fogh-Andersen N; Eidemak I; Løkkegaard H; Levin Nielsen S
    Scand J Clin Lab Invest Suppl; 1993; 214():61-5. PubMed ID: 8332853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin.
    Kamata K; Marumo F; Onoyama K
    Jpn Circ J; 1991 Jul; 55(7):649-56. PubMed ID: 1880896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin.
    Schiffl H
    Int J Artif Organs; 1992 Jun; 15(6):343-8. PubMed ID: 1639525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal anaemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease.
    Linde T; Wikström B; Andersson LG; Danielson BG
    Scand J Urol Nephrol; 1996 Apr; 30(2):115-20. PubMed ID: 8738056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin: proposal for a hematocrit most beneficial to hemodynamics.
    Tagawa H; Nagano M; Saito H; Umezu M; Yamakado M
    Clin Nephrol; 1991 Jan; 35(1):35-8. PubMed ID: 2007294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis.
    Pietrzak I; Bladek K; Bulikowski W
    Magnes Res; 2002 Dec; 15(3-4):229-36. PubMed ID: 12635877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats.
    Rodrigue ME; Lacasse-M S; Larivière R; Lebel M
    Can J Physiol Pharmacol; 2005 Jun; 83(6):467-75. PubMed ID: 16049546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy.
    Lebel M; Grose JH; Kingma I; Langlois S
    Clin Exp Hypertens; 1994 Sep; 16(5):565-75. PubMed ID: 7951163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemodynamics in hemodialysis patients treated with recombinant human erythropoietin.
    Nonnast-Daniel B; Schäffer J; Frei U
    Contrib Nephrol; 1989; 76():283-9; discussion 290-1. PubMed ID: 2684528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.
    Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Papageorgiou EG; Voulgaridou AI; Kokkalis AC; Antonelou MH; Papassideri IS
    Eur J Haematol; 2017 Jun; 98(6):590-600. PubMed ID: 28295628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.
    Takahashi K; Totsune K; Imai Y; Sone M; Nozuki M; Murakami O; Sekino H; Mouri T
    Clin Sci (Lond); 1993 Jan; 84(1):47-50. PubMed ID: 8382133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis.
    Martinez-Vea A; Bardají A; García C; Ridao C; Richart C; Oliver JA
    Am J Kidney Dis; 1992 Apr; 19(4):353-7. PubMed ID: 1532883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
    Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
    Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human erythropoietin (rhEPO) treatment potentiates growth hormone (GH) response to growth hormone releasing hormone (GHRH) stimulation in hemodialysis patients.
    Cremagnani L; Cantalamessa L; Orsatti A; Vigna L; Vallino F; Buccianti G
    Clin Nephrol; 1993 May; 39(5):282-6. PubMed ID: 8513607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.